Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Community Hematologist/Oncologist (CH/O) Barriers to CAR T Referral and Concerns with Possible in-Office CAR-T Administration

Speaker(s)

Pink S1, Jeune-Smith Y2, Klink A1, Gajra A1, Feinberg B3
1Cardinal Health Specialty Solutions, Dublin, OH, USA, 2Cardinal Health Specialty Solutions, Cedar Hill, TX, USA, 3Cardinal Health Specialty Solutions, ATLANTA, GA, USA

Background/Rationale: In 2017, the United States Food and Drug Administration approved chimeric antigen receptor T-cells (CAR T) therapy to treat patients with certain types of hematologic malignancies. Since cH/O play a critical role in patient access to CAR T therapy, this study aimed to understand challenges physicians face in referral of eligible patients and concerns with in-office administration as CAR T moves to out-patient delivery.

Method: This was a cross-sectional survey of cH/Os conducted at the Cardinal Health Specialty Solutions April 2021 virtual oncology summit. Physicians responded to survey questions that collected data on their practice setting and their knowledge and experience with CAR T therapy.

Results: A total of 68 cH/O participated in the survey. Regarding cH/O challenges for CAR T referral: 51% reported relationships with treatment center staff, 49% reported distance of treatment site from practice or patient’s residence, and 38% reported knowledge about the process as barriers for CAR T referrals. Regarding cH/O willingness to administer CAR T: 78% reported an inability to manage immediate complication, 68% reported concerns about hospitalizations within 24 hours of infusion, and 38% reported inability to bill for the service as primary barriers for in office CAR T administration.

Conclusion: CAR T therapy via cH/O referral is complicated by current tertiary site referral processes, while significant challenges may limit future cH/O out-patient administration when feasible. Stakeholder alignment is needed to address these concerns and barriers if CAR T therapy is to be optimized and made available to all eligible patients who might benefit from CAR T therapy.

Code

HSD44

Disease

Drugs, Oncology